Suggested remit: To appraise the clinical and cost effectiveness of belantamab mafodotin with bortezomib and dexamethasone within its marketing authorisation for treating relapsed or refractory multiple myeloma after 1 or more treatments.
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6212

Provisional Schedule

Committee meeting: 1 12 December 2024
Expected publication 05 March 2025

Project Team

Project lead Vonda Murray

Email enquiries


Key events during the development of the guidance:

Date Update
11 March 2024 Invitation to participate
15 January 2024 - 12 February 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6212
31 July 2023 Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in mid-March 2024. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission.
14 March 2023 In progress. DHSC referral received
23 November 2022 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual